In this Market Watch interview, Brad Wilson speaks with Professor Lars Søndergaard, Chief Medical Officer and Divisional Vice President, Medical Affairs for Abbott Structural Heart, about how transcatheter therapy has matured across the aortic, mitral and tricuspid space over the past two decades.

The discussion traces the trajectory of TAVR from the first commercial European cases in 2006 to today's broader device range and stronger evidence base, now reaching low-risk and younger populations. Prof Søndergaard reflects on emerging long-term durability data and whether transcatheter platforms can match surgical valves, and considers what expansion into younger patients means for lifetime management, including coronary access and TAVR-in-TAVR strategies planned at the index procedure. Much of the current momentum, he suggests, sits with the atrioventricular valves: newer mitral replacement devices with lower screen-failure rates and improved ease of use, alongside rapid progress in tricuspid repair and replacement. The conversation also addresses the strengthening role of the heart team as eligibility broadens, and the increasing centrality of imaging — from pre-procedural CT and echocardiography to 4D ICE and emerging AI-assisted tools that could help democratise complex procedures across lower-volume centres.

This video presents Abbott's perspective on these developments within the wider structural heart landscape, offering insight into how current technologies and clinical data are being interpreted and applied by industry.

Watch now for an industry view on where structural heart therapy is heading.